Cary Street Partners Asset Management LLC Sells 268 Shares of Becton, Dickinson and Company (NYSE:BDX)

Cary Street Partners Asset Management LLC lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 5.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,888 shares of the medical instruments supplier’s stock after selling 268 shares during the period. Cary Street Partners Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $1,192,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at approximately $25,000. Fortitude Family Office LLC bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $35,000. Venturi Wealth Management LLC increased its position in shares of Becton, Dickinson and Company by 552.0% during the fourth quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 138 shares in the last quarter. Arlington Trust Co LLC bought a new stake in Becton, Dickinson and Company in the 4th quarter valued at $41,000. Finally, MCF Advisors LLC lifted its holdings in shares of Becton, Dickinson and Company by 51.4% in the fourth quarter. MCF Advisors LLC now owns 212 shares of the medical instruments supplier’s stock valued at $52,000 after purchasing an additional 72 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

BDX opened at $233.81 on Thursday. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56. Becton, Dickinson and Company has a 12-month low of $229.40 and a 12-month high of $287.32. The business has a 50 day moving average of $238.75 and a 200-day moving average of $240.71. The stock has a market cap of $67.55 billion, a price-to-earnings ratio of 55.41, a PEG ratio of 1.94 and a beta of 0.45.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. Becton, Dickinson and Company’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.86 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.63%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio is 90.05%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares in the company, valued at $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Michael David Garrison sold 1,715 shares of the stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the topic of several research reports. Raymond James boosted their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Barclays raised their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, February 5th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.